Business Wire

BALDERTON-CAPITAL

12.8.2024 08:01:30 CEST | Business Wire | Press release

Share
Balderton Announces $1.3B in New Funds to Back Europe’s Top Entrepreneurs as They Build World-Changing Businesses

Balderton Capital, one of Europe’s leading technology venture capital firms, today announced its $615 million Early Stage Fund IX and $685 million Growth Fund II, to back Europe’s most ambitious entrepreneurs from seed stage through IPO.

At Balderton, we believe the best way to change the world is to build a business - and that many of these world-changing businesses will be built in Europe,” said Bernard Liautaud, Managing Partner at Balderton. “As a firm, our mission is simple: to be the partner of choice to the founders starting and growing those European technology companies. These new funds put us in a position to do just that.”

There was strong investor demand for Early Stage Fund IX and Growth Fund II, which marked the first time Balderton raised its early and growth funds simultaneously. The increasingly global mix of LPs in the firm’s funds have been attracted to Balderton’s European focus and track record of success during its 25 year history. This includes one of the largest and most prominent public state pensions in the United States, building out a selective European VC portfolio, and British Patient Capital, the UK's largest domestic investor in venture and venture growth opportunities.

There is now a long and diverse history of Europe as a key hub for global tech, with proven winners across sectors and countries. In just the last two years, Europe has established itself as a leader in AI, with London and Paris being the key innovation centres. The reasons for this are not surprising or new: world class institutions and engineers, a growing culture of entrepreneurialism, a developed funding ecosystem and, increasingly, third and fourth generation founders.

The growth of the European technology ecosystem has created strong returns for investors as well. European VC funds outperformed North American funds over both a 10 and 15 year period, according to data from Invest Europe and Cambridge Associates.

Since its founding in 2000, Balderton has invested in more than 275 technology companies from across Europe. The current portfolio includes global category leaders like Revolut, Dream Games, GoCardless, Contentful, Aircall, Wayve, Writer and PhotoRoom. Many previous portfolio companies have successfully exited, such as Darktrace, Depop, MySQL, Peakon, Recorded Future, Talend and THG. Balderton’s investment history spans technology sectors including AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplaces.

Beyond the hands-on support from its investment team, who have invaluable operational and entrepreneurial experience, Balderton offers a range of services to its founders and portfolio companies, including:

  • The Balderton Platform team, comprising experts in legal, finance, talent and people, marketing and sustainability
  • Executives in Residence - industry veterans with decades of experience as startup builders and operators, with expertise in areas including sales, engineering, product and legal
  • The Balderton Community of more than 700 leading European technology executives from across the portfolio, who come together for peer support, networking and events, and form one of the strongest startup networks in Europe

In addition, Balderton takes unprecedented steps to support founders through its industry-leading Balderton Founder Wellbeing and Performance platform. This covers executive coaching, peer to peer support in CEO Forums, a health and fitness program and access to a digital platform for parent founders.

With Balderton’s 65 team members across Europe, $1.3bn in new funds, and a strong portfolio of more than 125 companies, the firm is excited to continue its work of partnering with Europe’s top entrepreneurs as they build world-changing companies.

About Balderton Capital

Balderton Capital is a multistage venture firm with more than two decades of experience supporting Europe’s best founders from Seed to IPO. We have both early and growth funds and invest across the technology sector, with a proven track record backing AI, fintech, B2B SaaS, digital health, mobility, gaming and marketplace companies. Previous investments include Darktrace (LON: DARK), Depop, Flywire (NASDAQ: FLYW), Kobalt, MySQL, Nutmeg, Peakon, Recorded Future, Talend (NASDAQ: TLND) and THG (LON: THG). Balderton’s current portfolio includes: Aircall, Beauty Pie, Contentful, Dream Games, GoCardless, Lendable, Matillion, Merama, Photoroom, Revolut, Tibber, Wayve, Writer and ZOE.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808083911/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye